Sacubitril/valsartan significantly reduced cardiomyopathy risk in patients undergoing anthracycline chemotherapy, but further research is needed for broader applicability. Muvalaplin, an oral drug, ...

CHICAGO, Nov. 27, 2024 /PRNewswire/ -- Powerful Medical became the first company to win both the Best Science Startup and Overall Winner titles at the prestigious American Heart Association (AHA) ...

Get the latest news and updates from TCTMD. Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research ...

Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart ...